Man-Wah Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Man-Wah Tan has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth Skippington
Department of OMNI Bioinformatics, Genentech, South San Francisco, USA
6 shared publicationsMike Reichelt
Research Pathology, Genentech, Inc., South San Francisco, CA, USA
6 shared publicationsMin Xu
Department of Translational Immunology, Genentech Inc., South San Francisco, California, USA
6 shared publicationsVarnesh Tiku
Affiliations Infectious Diseases and Host-Microbe Interactions Department, Genentech Inc., San Francisco, California, United States of America, Department of Oncology, Gilead Sciences Inc., Foster City, California, United States of America
6 shared publicationsEric M. Kofoed
Department of Immunology and Infectious Diseases, Genentech, South San Francisco, USA
5 shared publications- Craig R. MacNair
Affiliation Infectious Diseases and Host-Microbe Interactions Department, Genentech Inc., San Francisco, California, United States of America
4 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8442
TREM1 signaling amplifies neutrophil-mediated inflammation in inflammatory bowel disease
In inflammatory bowel disease (IBD), complex immune dysregulation induces chronic inflammation. TREM1 is a receptor expressed on myeloid cells and is activated by ligands such as PGLYRP1 to amplify inflammatory responses. Here, we analyze the function of TREM1 signaling in neutrophil-driven inflammation, identifying two positive feedback loops. First, neutrophils activated by phorbol 12-myristate 13-acetate (PMA) or by bacteria release PGLYRP1, which forms a ligand complex with bacterial peptidoglycan and activates TREM1, thereby enhancing neutrophil degranulation, reactive oxygen species production, and NETosis. Second, TREM1 activation on monocytes promotes the secretion of chemokines and cytokines that recruit and activate additional neutrophils, further perpetuating inflammation. In vivo, TREM1 activation exacerbates colitis in mice, with the gut commensal bacterium Blautia faecis potentially contributing to human TREM1 activation in IBD. In biopsy samples from patients with IBD, an elevated TREM1 pathway signature is associated with inflamed tissue and treatment resistance in ulcerative colitis. Our findings thus highlight TREM1 as a regulator of mucosal inflammation, and a potential therapeutic target for IBD.
- 8 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8442
Open AccessTREM1 signaling amplifies neutrophil-mediated inflammation in inflammatory bowel disease
In inflammatory bowel disease (IBD), complex immune dysregulation induces chronic inflammation. TREM1 is a receptor expressed on myeloid cells and is activated by ligands such as PGLYRP1 to amplify inflammatory responses. Here, we analyze the function of TREM1 signaling in neutrophil-driven inflammation, identifying two positive feedback loops. First, neutrophils activated by phorbol 12-myristate 13-acetate (PMA) or by bacteria release PGLYRP1, which forms a ligand complex with bacterial peptidoglycan and activates TREM1, thereby enhancing neutrophil degranulation, reactive oxygen species production, and NETosis. Second, TREM1 activation on monocytes promotes the secretion of chemokines and cytokines that recruit and activate additional neutrophils, further perpetuating inflammation. In vivo, TREM1 activation exacerbates colitis in mice, with the gut commensal bacterium Blautia faecis potentially contributing to human TREM1 activation in IBD. In biopsy samples from patients with IBD, an elevated TREM1 pathway signature is associated with inflamed tissue and treatment resistance in ulcerative colitis. Our findings thus highlight TREM1 as a regulator of mucosal inflammation, and a potential therapeutic target for IBD.
- Open Access
- 26 May 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (5) , e1014256
Outer membrane vesicles hijack TIM-1 for cellular uptake
Outer membrane vesicles (OMVs) are nanoscale proteoliposomes shed by Gram-negative bacteria that mediate host-pathogen interactions and hold promise as platforms for vaccines and targeted drug delivery. Despite their biological and translational significance, the cellular mechanisms governing OMV entry into host cells remain poorly understood. Here, we demonstrate that E. coli OMVs are internalized by epithelial cells via clathrin-mediated, receptor-dependent endocytosis. Using a high-throughput screen of over 1,500 human single-pass transmembrane proteins, we identify T-cell immunoglobulin and mucin-domain 1 (TIM-1) as a strong OMV-binding receptor. Functional validation revealed that TIM-1 overexpression markedly increased OMV uptake, whereas TIM-1 knockout and antibody-mediated blockade significantly impaired internalization across multiple cell lines. Mechanistic studies demonstrate that TIM-1 binds to lipopolysaccharide (LPS) on the OMV surface via its phosphatidylserine-binding domain. Uptake of OMVs by TIM-1 triggers proinflammatory cytokine production which can be reduced by preventing this interaction. Additionally, OMVs from multiple bacterial species hijack TIM-1 for entry, making it an intriguing antivirulence strategy. Our findings establish TIM-1 as a critical host receptor mediating OMV uptake and provide a novel approach to modulate vesicle-driven pathogenesis and enhance OMV-based therapies.
- 26 May 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (5) , e1014256
Open AccessOuter membrane vesicles hijack TIM-1 for cellular uptake
Outer membrane vesicles (OMVs) are nanoscale proteoliposomes shed by Gram-negative bacteria that mediate host-pathogen interactions and hold promise as platforms for vaccines and targeted drug delivery. Despite their biological and translational significance, the cellular mechanisms governing OMV entry into host cells remain poorly understood. Here, we demonstrate that E. coli OMVs are internalized by epithelial cells via clathrin-mediated, receptor-dependent endocytosis. Using a high-throughput screen of over 1,500 human single-pass transmembrane proteins, we identify T-cell immunoglobulin and mucin-domain 1 (TIM-1) as a strong OMV-binding receptor. Functional validation revealed that TIM-1 overexpression markedly increased OMV uptake, whereas TIM-1 knockout and antibody-mediated blockade significantly impaired internalization across multiple cell lines. Mechanistic studies demonstrate that TIM-1 binds to lipopolysaccharide (LPS) on the OMV surface via its phosphatidylserine-binding domain. Uptake of OMVs by TIM-1 triggers proinflammatory cytokine production which can be reduced by preventing this interaction. Additionally, OMVs from multiple bacterial species hijack TIM-1 for entry, making it an intriguing antivirulence strategy. Our findings establish TIM-1 as a critical host receptor mediating OMV uptake and provide a novel approach to modulate vesicle-driven pathogenesis and enhance OMV-based therapies.
- Open Access
Outer Membrane Vesicles Hijack TIM-1 for Cellular Uptake
Outer membrane vesicles (OMVs) are nanoscale proteoliposomes shed by Gram-negative bacteria that mediate host-pathogen interactions and hold promise as platforms for vaccines and targeted drug delivery. Despite their biological and translational significance, the cellular mechanisms governing OMV entry into host cells remain poorly understood. Here, we demonstrate that E. coli OMVs are internalized by epithelial cells via clathrin-mediated, receptor-dependent endocytosis. Using a high-throughput screen of over 1,500 human single-pass transmembrane proteins, we identify T-cell immunoglobulin and mucin-domain 1 (TIM-1) as a strong OMV-binding receptor. Functional validation revealed that TIM-1 overexpression markedly increased OMV uptake, whereas TIM-1 knockout and antibody-mediated blockade significantly impaired internalization across multiple cell lines. Mechanistic studies demonstrate that TIM-1 binds to lipopolysaccharide (LPS) on the OMV surface via its known phosphatidylserine-binding domain. Uptake of OMVs by TIM-1 triggers proinflammatory cytokine production which can be reduced by preventing this interaction. Additionally, OMVs from multiple bacterial species hijack TIM-1 for entry, making it an intriguing antivirulence strategy. Our findings establish TIM-1 as a critical host receptor mediating OMV uptake and provide a novel approach to modulate vesicle-driven pathogenesis and enhance OMV-based therapies.
Open AccessOuter Membrane Vesicles Hijack TIM-1 for Cellular Uptake
Outer membrane vesicles (OMVs) are nanoscale proteoliposomes shed by Gram-negative bacteria that mediate host-pathogen interactions and hold promise as platforms for vaccines and targeted drug delivery. Despite their biological and translational significance, the cellular mechanisms governing OMV entry into host cells remain poorly understood. Here, we demonstrate that E. coli OMVs are internalized by epithelial cells via clathrin-mediated, receptor-dependent endocytosis. Using a high-throughput screen of over 1,500 human single-pass transmembrane proteins, we identify T-cell immunoglobulin and mucin-domain 1 (TIM-1) as a strong OMV-binding receptor. Functional validation revealed that TIM-1 overexpression markedly increased OMV uptake, whereas TIM-1 knockout and antibody-mediated blockade significantly impaired internalization across multiple cell lines. Mechanistic studies demonstrate that TIM-1 binds to lipopolysaccharide (LPS) on the OMV surface via its known phosphatidylserine-binding domain. Uptake of OMVs by TIM-1 triggers proinflammatory cytokine production which can be reduced by preventing this interaction. Additionally, OMVs from multiple bacterial species hijack TIM-1 for entry, making it an intriguing antivirulence strategy. Our findings establish TIM-1 as a critical host receptor mediating OMV uptake and provide a novel approach to modulate vesicle-driven pathogenesis and enhance OMV-based therapies.
- Open Access
- 4 December 2025
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 11 (1) , 225
A microbiota-derived bile acid modulates biofilm formation by the probiotic strain Escherichia coli Nissle 1917
Bacteria that colonize the human gut must withstand a variety of stressors, including detergent-like compounds known as bile acids. Here, we investigated how bile acids found in the human cecum and colon impact the behavior of the probiotic strain Escherichia coli Nissle 1917 (EcN). We found that lithocholic acid (LCA), which is a microbiota-derived secondary bile acid, promotes the formation of a distinctive surface-coating biofilm by EcN, including on an organoid-derived model of the human colonic epithelium. Mechanistic investigations revealed that LCA upregulates the production of several components of flagella, which are essential for LCA-induced biofilm formation and form part of the biofilm matrix. Furthermore, LCA-induced biofilm formation helps EcN compete against certain pathogenic strains. Taken together, our findings shed light on how an abundant colonic metabolite influences the behavior of a clinically proven probiotic strain, triggering the formation of biofilms that may contribute to pathogen suppression.
- 4 December 2025
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 11 (1) , 225
Open AccessA microbiota-derived bile acid modulates biofilm formation by the probiotic strain Escherichia coli Nissle 1917
Bacteria that colonize the human gut must withstand a variety of stressors, including detergent-like compounds known as bile acids. Here, we investigated how bile acids found in the human cecum and colon impact the behavior of the probiotic strain Escherichia coli Nissle 1917 (EcN). We found that lithocholic acid (LCA), which is a microbiota-derived secondary bile acid, promotes the formation of a distinctive surface-coating biofilm by EcN, including on an organoid-derived model of the human colonic epithelium. Mechanistic investigations revealed that LCA upregulates the production of several components of flagella, which are essential for LCA-induced biofilm formation and form part of the biofilm matrix. Furthermore, LCA-induced biofilm formation helps EcN compete against certain pathogenic strains. Taken together, our findings shed light on how an abundant colonic metabolite influences the behavior of a clinically proven probiotic strain, triggering the formation of biofilms that may contribute to pathogen suppression.
- Open Access
- 22 October 2025
- Published by Springer Nature in Nature
- Vol. 648 (8092) , 166-172
Enteropathogenic bacteria evade ROCK-driven epithelial cell extrusion
Diverse pathogen-encoded virulence factors disable apoptosis, pyroptosis or necroptosis, the host cell death programs that remove infected cells1. In the intestine, the extrusion of infected cells into the lumen for elimination provides an additional layer of host defence, but no virulence mechanisms that target the cytoskeletal changes required are known2. Here we show that the Escherichia coli ubiquitin ligase NleL is an inhibitor of intestinal epithelial cell (IEC) extrusion, targeting caspase-4, ROCK1 and ROCK2 for proteasomal degradation. Genetic deletion of Rock1 and Rock2 from cultured IECs diminished inflammasome-induced IEC extrusion. Moreover, mice with Rock1- and Rock2-deficient IECs were less effective than wild-type mice at constraining the numbers of Citrobacter rodentium in the colon. Notably, NleL-deficient C. rodentium triggered more IEC extrusion than did wild-type C. rodentium, resulting in diminished colonization of the colon in infected mice. Our work highlights a host–pathogen arms race focused on dynamic regulation of the host epithelial barrier.
- 22 October 2025
- Published by Springer Nature in Nature
- Vol. 648 (8092) , 166-172
Open AccessEnteropathogenic bacteria evade ROCK-driven epithelial cell extrusion
Diverse pathogen-encoded virulence factors disable apoptosis, pyroptosis or necroptosis, the host cell death programs that remove infected cells1. In the intestine, the extrusion of infected cells into the lumen for elimination provides an additional layer of host defence, but no virulence mechanisms that target the cytoskeletal changes required are known2. Here we show that the Escherichia coli ubiquitin ligase NleL is an inhibitor of intestinal epithelial cell (IEC) extrusion, targeting caspase-4, ROCK1 and ROCK2 for proteasomal degradation. Genetic deletion of Rock1 and Rock2 from cultured IECs diminished inflammasome-induced IEC extrusion. Moreover, mice with Rock1- and Rock2-deficient IECs were less effective than wild-type mice at constraining the numbers of Citrobacter rodentium in the colon. Notably, NleL-deficient C. rodentium triggered more IEC extrusion than did wild-type C. rodentium, resulting in diminished colonization of the colon in infected mice. Our work highlights a host–pathogen arms race focused on dynamic regulation of the host epithelial barrier.
- Open Access
A microbiota-derived bile acid modulates biofilm formation by the probiotic strain Escherichia coli Nissle 1917
Bacteria that colonize the human gut must withstand a variety of stressors, including detergent-like compounds known as bile acids. Here, we investigated how bile acids found in the human cecum and colon impact the behavior of the probiotic strain Escherichia coli Nissle 1917 (EcN). We found that lithocholic acid (LCA), which is a microbiota-derived secondary bile acid, promotes the formation of a distinctive surface-coating biofilm by EcN, including on an organoid-derived model of the human colonic epithelium. Mechanistic investigations revealed that LCA upregulates the production of several components of flagella, which are essential for LCA-induced biofilm formation and form part of the biofilm matrix. Furthermore, LCA-induced biofilm formation helps EcN compete against certain pathogenic strains. Taken together, our findings shed light on how an abundant colonic metabolite influences the behavior of a clinically-proven probiotic strain, triggering the formation of biofilms that may contribute to pathogen suppression.
Open AccessA microbiota-derived bile acid modulates biofilm formation by the probiotic strain Escherichia coli Nissle 1917
Bacteria that colonize the human gut must withstand a variety of stressors, including detergent-like compounds known as bile acids. Here, we investigated how bile acids found in the human cecum and colon impact the behavior of the probiotic strain Escherichia coli Nissle 1917 (EcN). We found that lithocholic acid (LCA), which is a microbiota-derived secondary bile acid, promotes the formation of a distinctive surface-coating biofilm by EcN, including on an organoid-derived model of the human colonic epithelium. Mechanistic investigations revealed that LCA upregulates the production of several components of flagella, which are essential for LCA-induced biofilm formation and form part of the biofilm matrix. Furthermore, LCA-induced biofilm formation helps EcN compete against certain pathogenic strains. Taken together, our findings shed light on how an abundant colonic metabolite influences the behavior of a clinically-proven probiotic strain, triggering the formation of biofilms that may contribute to pathogen suppression.
- Open Access
- 24 October 2024
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 206 (10) , e0010224
Differential effects of inosine monophosphate dehydrogenase (IMPDH/GuaB) inhibition in Acinetobacter baumannii and Escherichia coli
Inosine 5′-monophosphate dehydrogenase (IMPDH), known as GuaB in bacteria, catalyzes the rate-limiting step in de novo guanine biosynthesis and is conserved from humans to bacteria. We developed a series of potent inhibitors that selectively target GuaB over its human homolog. Here, we show that these GuaB inhibitors are bactericidal, generate phenotypic signatures that are distinct from other antibiotics, and elicit different time-kill kinetics and regulatory responses in two important Gram-negative pathogens: Acinetobacter baumannii and Escherichia coli . Specifically, the GuaB inhibitor G6 rapidly kills A. baumannii but only kills E. coli after 24 h. After exposure to G6, the expression of genes involved in purine biosynthesis and stress responses change in opposite directions while siderophore biosynthesis is downregulated in both species. Our results suggest that different species respond to GuaB inhibition using distinct regulatory programs and possibly explain the different bactericidal kinetics upon GuaB inhibition. The comparison highlights opportunities for developing GuaB inhibitors as novel antibiotics. IMPORTANCE: A. baumannii is a priority bacterial pathogen for which development of new antibiotics is urgently needed due to the emergence of multidrug resistance. We recently developed a series of specific inhibitors against GuaB, a bacterial inosine 5′-monophosphate dehydrogenase, and achieved sub-micromolar minimum inhibitory concentrations against A. baumannii . GuaB catalyzes the rate-limiting step of de novo guanine biosynthesis and is highly conserved across bacterial pathogens. This study shows that inhibition of GuaB induced a bacterial morphological profile distinct from that of other classes of antibiotics, highlighting a novel mechanism of action. Moreover, our transcriptomic analysis showed that regulation of de novo purine biosynthesis and stress responses of A. baumannii upon GuaB inhibition differed significantly from that of E. coli .
- 24 October 2024
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 206 (10) , e0010224
Open AccessDifferential effects of inosine monophosphate dehydrogenase (IMPDH/GuaB) inhibition in Acinetobacter baumannii and Escherichia coli
Inosine 5′-monophosphate dehydrogenase (IMPDH), known as GuaB in bacteria, catalyzes the rate-limiting step in de novo guanine biosynthesis and is conserved from humans to bacteria. We developed a series of potent inhibitors that selectively target GuaB over its human homolog. Here, we show that these GuaB inhibitors are bactericidal, generate phenotypic signatures that are distinct from other antibiotics, and elicit different time-kill kinetics and regulatory responses in two important Gram-negative pathogens: Acinetobacter baumannii and Escherichia coli . Specifically, the GuaB inhibitor G6 rapidly kills A. baumannii but only kills E. coli after 24 h. After exposure to G6, the expression of genes involved in purine biosynthesis and stress responses change in opposite directions while siderophore biosynthesis is downregulated in both species. Our results suggest that different species respond to GuaB inhibition using distinct regulatory programs and possibly explain the different bactericidal kinetics upon GuaB inhibition. The comparison highlights opportunities for developing GuaB inhibitors as novel antibiotics. IMPORTANCE: A. baumannii is a priority bacterial pathogen for which development of new antibiotics is urgently needed due to the emergence of multidrug resistance. We recently developed a series of specific inhibitors against GuaB, a bacterial inosine 5′-monophosphate dehydrogenase, and achieved sub-micromolar minimum inhibitory concentrations against A. baumannii . GuaB catalyzes the rate-limiting step of de novo guanine biosynthesis and is highly conserved across bacterial pathogens. This study shows that inhibition of GuaB induced a bacterial morphological profile distinct from that of other classes of antibiotics, highlighting a novel mechanism of action. Moreover, our transcriptomic analysis showed that regulation of de novo purine biosynthesis and stress responses of A. baumannii upon GuaB inhibition differed significantly from that of E. coli .
- Open Access
- 16 October 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (10) , e0089724
Discovery of GuaB inhibitors with efficacy against Acinetobacter baumannii infection
Guanine nucleotides are required for growth and viability of cells due to their structural role in DNA and RNA, and their regulatory roles in translation, signal transduction, and cell division. The natural antibiotic mycophenolic acid (MPA) targets the rate-limiting step in de novo guanine nucleotide biosynthesis executed by inosine-5´-monophosphate dehydrogenase (IMPDH). MPA is used clinically as an immunosuppressant, but whether in vivo inhibition of bacterial IMPDH (GuaB) is a valid antibacterial strategy is controversial. Here, we describe the discovery of extremely potent small molecule GuaB inhibitors (GuaBi) specific to pathogenic bacteria with a low frequency of on-target spontaneous resistance and bactericidal efficacy in vivo against Acinetobacter baumannii mouse models of infection. The spectrum of GuaBi activity includes multidrug-resistant pathogens that are a critical priority of new antibiotic development. Co-crystal structures of A. baumannii, Staphylococcus aureus , and Escherichia coli GuaB proteins bound to inhibitors show comparable binding modes of GuaBi across species and identifies key binding site residues that are predictive of whole-cell activity across both Gram-positive and Gram-negative clades of Bacteria. The clear in vivo efficacy of these small molecule GuaB inhibitors in a model of A. baumannii infection validates GuaB as an essential antibiotic target. IMPORTANCE: The emergence of multidrug-resistant bacteria worldwide has renewed interest in discovering antibiotics with novel mechanism of action. For the first time ever, we demonstrate that pharmacological inhibition of de novo guanine biosynthesis is bactericidal in a mouse model of Acinetobacter baumannii infection. Structural analyses of novel inhibitors explain differences in biochemical and whole-cell activity across bacterial clades and underscore why this discovery may have broad translational impact on treatment of the most recalcitrant bacterial infections.
- 16 October 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (10) , e0089724
Open AccessDiscovery of GuaB inhibitors with efficacy against Acinetobacter baumannii infection
Guanine nucleotides are required for growth and viability of cells due to their structural role in DNA and RNA, and their regulatory roles in translation, signal transduction, and cell division. The natural antibiotic mycophenolic acid (MPA) targets the rate-limiting step in de novo guanine nucleotide biosynthesis executed by inosine-5´-monophosphate dehydrogenase (IMPDH). MPA is used clinically as an immunosuppressant, but whether in vivo inhibition of bacterial IMPDH (GuaB) is a valid antibacterial strategy is controversial. Here, we describe the discovery of extremely potent small molecule GuaB inhibitors (GuaBi) specific to pathogenic bacteria with a low frequency of on-target spontaneous resistance and bactericidal efficacy in vivo against Acinetobacter baumannii mouse models of infection. The spectrum of GuaBi activity includes multidrug-resistant pathogens that are a critical priority of new antibiotic development. Co-crystal structures of A. baumannii, Staphylococcus aureus , and Escherichia coli GuaB proteins bound to inhibitors show comparable binding modes of GuaBi across species and identifies key binding site residues that are predictive of whole-cell activity across both Gram-positive and Gram-negative clades of Bacteria. The clear in vivo efficacy of these small molecule GuaB inhibitors in a model of A. baumannii infection validates GuaB as an essential antibiotic target. IMPORTANCE: The emergence of multidrug-resistant bacteria worldwide has renewed interest in discovering antibiotics with novel mechanism of action. For the first time ever, we demonstrate that pharmacological inhibition of de novo guanine biosynthesis is bactericidal in a mouse model of Acinetobacter baumannii infection. Structural analyses of novel inhibitors explain differences in biochemical and whole-cell activity across bacterial clades and underscore why this discovery may have broad translational impact on treatment of the most recalcitrant bacterial infections.
- Top Cited Papers
- 11 December 2023
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 22 (5) , 262-275
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
Resistance threatens to render antibiotics — which are essential for modern medicine — ineffective, thus posing a threat to human health. The discovery of novel classes of antibiotics able to overcome resistance has been stalled for decades, with the developmental pipeline relying almost entirely on variations of existing chemical scaffolds. Unfortunately, this approach has been unable to keep pace with resistance evolution, necessitating new therapeutic strategies. In this Review, we highlight recent efforts to discover non-traditional antimicrobials, specifically describing the advantages and limitations of antimicrobial peptides and macrocycles, antibodies, bacteriophages and antisense oligonucleotides. These approaches have the potential to stem the tide of resistance by expanding the physicochemical property space and target spectrum occupied by currently approved antibiotics.
- 11 December 2023
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 22 (5) , 262-275
Top Cited PapersAlternative therapeutic strategies to treat antibiotic-resistant pathogens
Resistance threatens to render antibiotics — which are essential for modern medicine — ineffective, thus posing a threat to human health. The discovery of novel classes of antibiotics able to overcome resistance has been stalled for decades, with the developmental pipeline relying almost entirely on variations of existing chemical scaffolds. Unfortunately, this approach has been unable to keep pace with resistance evolution, necessitating new therapeutic strategies. In this Review, we highlight recent efforts to discover non-traditional antimicrobials, specifically describing the advantages and limitations of antimicrobial peptides and macrocycles, antibodies, bacteriophages and antisense oligonucleotides. These approaches have the potential to stem the tide of resistance by expanding the physicochemical property space and target spectrum occupied by currently approved antibiotics.
- Open Access
- 30 August 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1237164
Bacterial biofilms in the human body: prevalence and impacts on health and disease
Bacterial biofilms can be found in most environments on our planet, and the human body is no exception. Consisting of microbial cells encased in a matrix of extracellular polymers, biofilms enable bacteria to sequester themselves in favorable niches, while also increasing their ability to resist numerous stresses and survive under hostile circumstances. In recent decades, biofilms have increasingly been recognized as a major contributor to the pathogenesis of chronic infections. However, biofilms also occur in or on certain tissues in healthy individuals, and their constituent species are not restricted to canonical pathogens. In this review, we discuss the evidence for where, when, and what types of biofilms occur in the human body, as well as the diverse ways in which they can impact host health under homeostatic and dysbiotic states.
- 30 August 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1237164
Open AccessBacterial biofilms in the human body: prevalence and impacts on health and disease
Bacterial biofilms can be found in most environments on our planet, and the human body is no exception. Consisting of microbial cells encased in a matrix of extracellular polymers, biofilms enable bacteria to sequester themselves in favorable niches, while also increasing their ability to resist numerous stresses and survive under hostile circumstances. In recent decades, biofilms have increasingly been recognized as a major contributor to the pathogenesis of chronic infections. However, biofilms also occur in or on certain tissues in healthy individuals, and their constituent species are not restricted to canonical pathogens. In this review, we discuss the evidence for where, when, and what types of biofilms occur in the human body, as well as the diverse ways in which they can impact host health under homeostatic and dysbiotic states.